TWA
NRIX icon

TCI Wealth Advisors’s Nurix Therapeutics NRIX Stock Holding History

TCI Wealth Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-355
Closed -$3.15K – 1517
2023
Q1 		$3.15K Buy
+355
New +$3.7K ﹤0.01% 1831
2022
Q2 		– Sell
-269
Closed -$4K – 2443
2022
Q1 		$4K Buy
269
+199
+284% +$3.53K ﹤0.01% 1747
2021
Q4 		$2K Buy
70
+3
+4% +$91 ﹤0.01% 2100
2021
Q3 		$2K Hold
67
– – ﹤0.01% 2156
2021
Q2 		$2K Buy
+67
New +$1.97K ﹤0.01% 2051

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

TCI Wealth Advisors's NRIX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Nurix Therapeutics (NRIX) in Q2 2023, closing a stake of 355 shares — an estimated $3.15K sold.

TCI Wealth Advisors first reported a position in NRIX in Q2 2021 and held it in 5 quarters. The position peaked at $4K in Q1 2022. 126 funds tracked by Wall St. Rank hold NRIX as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Nurix Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 355 Nurix Therapeutics shares in Q2 2023, an estimated $3.15K.
  • TCI Wealth Advisors first reported a position in Nurix Therapeutics in Q2 2021 and held it in 5 quarters.
  • TCI Wealth Advisors's Nurix Therapeutics position peaked at $4K in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.